Freezing plus immunotherapy for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new approach that combines freezing the tumor from inside the stomach with an immunotherapy drug that helps your immune system fight cancer. It is for people with advanced stomach cancer that has not responded to previous chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage IV stomach cancer that has spread or cannot be removed with surgery.
- You need to have tried 1 or 2 standard chemotherapy treatments, and your cancer kept growing despite them.
- You must be between 18 and 79 years old.
- Your cancer type must be adenocarcinoma or neuroendocrine tumor, and your doctor expects you to live at least 3 more months.
- Your liver, kidney, and blood counts must be within certain limits, and you must be able to manage daily activities (ECOG score 2 or lower).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment that freezes the tumor (cryoablation) combined with an immunotherapy drug (PD-1 inhibitor) for people with advanced stomach cancer. It aims to see if this combination helps keep the cancer under control longer than standard therapy alone.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.